Acalabrutinib ups PFS in treatment-naïve CLL patients
11 Dec 2019
byChristina Lau
Acalabrutinib, when combined with obinutuzumab or used as monotherapy, significantly improves progression-free survival (PFS) by 80–90 percent vs chemoimmunotherapy in patients with previously-untreated chronic lymphocytic leukaemia (CLL), results of the phase III ELEVATE TN trial have shown.